Ixoberogene soroparvovec

Gene therapy / editing

Also known as ADVM-022

Phase 3Mechanism not established
Phase 3underway

Evidence outlook · registrational

Wet Age-Related Macular Degeneration: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2026-12-22.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Wet Age-Related Macular Degeneration
NCT07482176 · Adverum Biotechnologies, Inc.
2026-03-16 – 2031-10-20 · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
What this study did
NCT06856577 · Adverum Biotechnologies, Inc.
2025-02-28 – 2030-11-23 · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
What this study did
Phase 2 (3)
Wet Age-Related Macular Degeneration
NCT07630649 · Adverum Biotechnologies, Inc.
2026-06-02 – 2031-06 · Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
What this study did
NCT05536973 · Adverum Biotechnologies, Inc.
2022-08-23 – 2028-08 · Neovascular Age-related Macular Degeneration
What this study did
Other / comorbidity
NCT04418427 · Adverum Biotechnologies, Inc.
2020-05-28 – 2023-06-14 · Diabetic Macular Edema, Diabetic Retinopathy
What this study did
Phase 1 (1)
Wet Age-Related Macular Degeneration
NCT03748784 · Adverum Biotechnologies, Inc.
2018-11-14 – 2022-06-22 · Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
What this study did

Competitive landscape

This drug's own stage for Wet Age-Related Macular Degeneration: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ixoberogene Soroparvovec: this drugPhase 3Gene therapy / editing—not yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eylea)ApprovedProtein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Reliable signal
NCT00509795: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0)
NCT00637377: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (At week 52): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 95.62% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 96.27% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 95.56% vs Ranibizumab 0.5mg Q4 94.42%
Aflibercept-Ayyh (Pavblu)ApprovedProtein / enzyme therapeuticVEGF-AReliable signal
NCT04270747: Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97)
Aflibercept-Boav (Eydenzelt)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)ApprovedProtein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Brolucizumab-DbllApprovedAntibody fragmentVEGF-AReliable signalNo reviewed efficacy summary in this indication
FaricimabApprovedMultispecific antibodyAngiopoietin-2 / VEGF-AReliable signal
NCT03823287: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 5.8 vs 5.1 letters, adjusted mean difference 0.7 (95% CI -1.1 to 2.5); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
NCT03823300: BCVA change averaged over weeks 40 to 48, faricimab vs aflibercept: 6.6 vs 6.6 letters, adjusted mean difference 0.0 (95% CI -1.7 to 1.8); lower bound above the -4 letter non-inferiority margin (CT.gov posted results).
Ranibizumab (Lucentis)ApprovedAntibody fragmentVEGF-APartial signalNo reviewed efficacy summary in this indication
Ranibizumab-Eqrn (Cimerli)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Ranibizumab-Nuna (Byooviz)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Axitinib Intravitreal Implant (OTX-TKI)Phase 3Small moleculeVEGF receptors + PDGF receptorsPartial signal
NCT06223958: Superiority primary endpoint at week 36: 74.1% with AXPAXLI vs 55.8% with aflibercept 2 mg lost fewer than 15 ETDRS letters (2026-02-17).
Tarcocimab TedromerPhase 3Monoclonal antibodyVEGF-APartial signal
NCT04964089: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76)
NCT06556368: Primary endpoint, BCVA: met (p=0.0007) (Kodiak topline, 2026-09-28).

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ixoberogene soroparvovec to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Wet Age-Related Macular DegenerationActive not recruiting
Est. primary completion 2026-12-22 · NCT06856577 · CT.gov ↗
What to watch
2027 (1)
November 2027 (1)
Phase 3Wet Age-Related Macular DegenerationRecruiting
Est. primary completion 2027-11-15 · NCT07482176 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 2Wet Age-Related Macular DegenerationRecruiting
Est. primary completion 2031-06 · NCT07630649 · CT.gov ↗
What to watch

See the full readout calendar ↗